This suggests a clinical benefit of clinical application of predictive algorithms to test for CDK12-d, specifically when considering the application of CHK1 inhibitors in prostate, ovary, and breast cancer treatment (Paculová et al., 2017). This evidence concerns the gene CHEK1 and breast cancer.